adenine has been researched along with Kidney Diseases in 200 studies
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively." | 9.12 | Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. ( Arterburn, S; Borroto-Esoda, K; Brosgart, C; Chuck, S; Colombo, M; Hadziyannis, S; Lai, CL; Neuhaus, P; Samuel, D; Schiff, E; Terrault, N; Tillmann, H; Villeneuve, JP; Zeuzem, S, 2007) |
| "Long-term adefovir dipivoxil therapy is connected to renal dysfunction in chronic hepatitis B, necessitating the monitoring of kidney function." | 8.93 | Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. ( Cheng, F; Deng, Y; Kang, J; Luo, Q; Zeng, W; Zhang, D; Zhong, S, 2016) |
| "We investigated antifibrotic effects of capsaicin in two mouse renal fibrosis models as follows: C57BL/6J mice were subjected to unilateral ureteral obstruction (UUO) and fed with an adenine-rich diet." | 8.12 | Capsaicin ameliorates renal fibrosis by inhibiting TGF-β1-Smad2/3 signaling. ( Li, X; Liu, Z; Meng, D; Tang, S; Wang, H; Wang, W; Wu, Y; Xia, W; Zhang, J; Zhou, X, 2022) |
| "Adefovir dipivoxil (ADV) is one of the most important nucleostide analogues currently in use for the treatment of chronic hepatitis B virus (HBV) infection." | 7.91 | Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible? ( Dai, ZJ; Jin, J; Pan, YJ; Qian, YY; Ruan, LY; Shi, MT; Wu, CM; Zhu, YX, 2019) |
| "Renal dysfunction and Fanconi's syndrome associated with hypophosphatemia caused by long-term administration of low-dose adefovir dipivoxil (ADV) has been reported in recent years." | 7.80 | Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Tanaka, M, 2014) |
| "Chronic hepatitis B patients (CHB) treated with adefovir were followed up to evaluate nephrotoxicity and its outcome." | 7.79 | Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. ( Aung, MO; Chiu, LL; Dan, YY; Gowans, M; Hartono, JL; Khoo, MJ; Koay, E; Lee, GH; Lee, YM; Lim, K; Lim, SG; Low, HC; Soon, C; Tan, PS; Thwin, MA, 2013) |
| " Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin." | 7.79 | Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. ( Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M, 2013) |
| "Tenofovir is a nucleotide reverse-transcriptase inhibitor approved for treatment of human immunodeficiency virus infection, as well as chronic hepatitis B (CHB)." | 7.78 | Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. ( Baqai, S; Clark, MD; Gish, RG; Kane, SD; Mangahas, MF; Shaw, RE, 2012) |
| "To study the preventive and therapeutic effects of Quercetin (Que) on hyperuricemia and renal failure in rats." | 7.77 | [Preventive and therapeutic effects of quercetin on hyperuricemia and renal injury in rats]. ( Fu, R; He, W; Yao, F; Zhang, R, 2011) |
| " In this study, we showed elevated HMGB1 expression in renal granulomas in rats with crystal-induced granulomatous nephritis caused by feeding an adenine-rich diet." | 7.76 | High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. ( Biswas, KK; Hashiguchi, T; Kawahara, K; Lotz, M; Maruyama, I; Nitanda, T; Oyama, Y; Tancharoen, S; Taniguchi, N; Uchimura, T; Umekita, Y, 2010) |
| "Tenofovir-related tubule damage characterized by Fanconi syndrome, renal insufficiency and nephrogenic diabetes insipidus has been reported in the adult HIV-infected population." | 7.73 | Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. ( Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A, 2006) |
| "Renal fibrosis is a common pathological feature of the progression of chronic kidney disease." | 5.46 | Valproic acid attenuates renal fibrosis through the induction of autophagy. ( Doi, S; Doi, T; Kawaoka, K; Masaki, T; Nakashima, A; Ueno, T; Yamada, K, 2017) |
| " Modification of the dosing interval or discontinuation of ADV was required in seven and three patients, respectively, and none of them showed a further decline in the eGFR." | 5.38 | Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. ( Cho, HC; Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012) |
| "Gout is principally a disease of middle-aged men." | 5.26 | Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family. ( Cameron, JS; Dillon, MJ; Farebrother, DA; Pincott, JR; Simmons, HA; Warren, DJ, 1981) |
| "Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively." | 5.12 | Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. ( Arterburn, S; Borroto-Esoda, K; Brosgart, C; Chuck, S; Colombo, M; Hadziyannis, S; Lai, CL; Neuhaus, P; Samuel, D; Schiff, E; Terrault, N; Tillmann, H; Villeneuve, JP; Zeuzem, S, 2007) |
| "The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations." | 4.98 | Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. ( Asriel, B; Chan, L; Eaton, EF; Wyatt, CM, 2018) |
| "Long-term adefovir dipivoxil therapy is connected to renal dysfunction in chronic hepatitis B, necessitating the monitoring of kidney function." | 4.93 | Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. ( Cheng, F; Deng, Y; Kang, J; Luo, Q; Zeng, W; Zhang, D; Zhong, S, 2016) |
| "We investigated antifibrotic effects of capsaicin in two mouse renal fibrosis models as follows: C57BL/6J mice were subjected to unilateral ureteral obstruction (UUO) and fed with an adenine-rich diet." | 4.12 | Capsaicin ameliorates renal fibrosis by inhibiting TGF-β1-Smad2/3 signaling. ( Li, X; Liu, Z; Meng, D; Tang, S; Wang, H; Wang, W; Wu, Y; Xia, W; Zhang, J; Zhou, X, 2022) |
| " MYDGF164 alleviated capillary rarefaction, hypoxia, renal fibrosis, and tubular atrophy in UUO mice and in adenine-induced CKD rats." | 4.12 | Mucin-fused myeloid-derived growth factor (MYDGF164) exhibits a prolonged serum half-life and alleviates fibrosis in chronic kidney disease. ( Du, P; Wang, H; Wang, T; Yang, M; Yin, H, 2022) |
| " The efficacy of the CTGF vaccine on renal fibrosis was evaluated in adenine-induced CKD and unilateral ureteral obstruction (UUO) murine models." | 4.12 | Vaccination against connective tissue growth factor attenuates the development of renal fibrosis. ( Azegami, T; Hayashi, K; Hishikawa, A; Itoh, H; Nakamichi, R; Nakayama, T; Sugita, E; Yoshimoto, N, 2022) |
| "Adefovir dipivoxil (ADV) is one of the most important nucleostide analogues currently in use for the treatment of chronic hepatitis B virus (HBV) infection." | 3.91 | Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible? ( Dai, ZJ; Jin, J; Pan, YJ; Qian, YY; Ruan, LY; Shi, MT; Wu, CM; Zhu, YX, 2019) |
| "To investigate the predictors of proximal kidney tubular dysfunction (PKTD) induced by adefovir dipivoxil (ADV) treatment for chronic hepatitis B." | 3.81 | Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B. ( Furusyo, N; Harada, Y; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K, 2015) |
| " MR images were acquired on two mouse models of kidney injury: adenine-induced chronic kidney disease (CKD) and rhabdomyolysis-induced acute kidney injury (AKI)." | 3.80 | Assessment with unenhanced MRI techniques of renal morphology and hemodynamic changes during acute kidney injury and chronic kidney disease in mice. ( Abramovitch, R; Axelrod, JH; Heyman, SN; Milman, Z; Nachmansson, N, 2014) |
| "Renal dysfunction and Fanconi's syndrome associated with hypophosphatemia caused by long-term administration of low-dose adefovir dipivoxil (ADV) has been reported in recent years." | 3.80 | Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Tanaka, M, 2014) |
| " The risks associated with initiating tenofovir immediately in pregnant women before reviewing serum creatinine results may be limited, and the benefits of rapid ART initiation in pregnancy may outweigh possible risks of nephrotoxicity." | 3.79 | Low prevalence of renal dysfunction in HIV-infected pregnant women: implications for guidelines for the prevention of mother-to-child transmission of HIV. ( Bekker, LG; Kamkuemah, M; Kaplan, R; Myer, L, 2013) |
| " Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin." | 3.79 | Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. ( Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M, 2013) |
| "Chronic hepatitis B patients (CHB) treated with adefovir were followed up to evaluate nephrotoxicity and its outcome." | 3.79 | Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. ( Aung, MO; Chiu, LL; Dan, YY; Gowans, M; Hartono, JL; Khoo, MJ; Koay, E; Lee, GH; Lee, YM; Lim, K; Lim, SG; Low, HC; Soon, C; Tan, PS; Thwin, MA, 2013) |
| "Tenofovir is a nucleotide reverse-transcriptase inhibitor approved for treatment of human immunodeficiency virus infection, as well as chronic hepatitis B (CHB)." | 3.78 | Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. ( Baqai, S; Clark, MD; Gish, RG; Kane, SD; Mangahas, MF; Shaw, RE, 2012) |
| "To study the preventive and therapeutic effects of Quercetin (Que) on hyperuricemia and renal failure in rats." | 3.77 | [Preventive and therapeutic effects of quercetin on hyperuricemia and renal injury in rats]. ( Fu, R; He, W; Yao, F; Zhang, R, 2011) |
| " In this study, we showed elevated HMGB1 expression in renal granulomas in rats with crystal-induced granulomatous nephritis caused by feeding an adenine-rich diet." | 3.76 | High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. ( Biswas, KK; Hashiguchi, T; Kawahara, K; Lotz, M; Maruyama, I; Nitanda, T; Oyama, Y; Tancharoen, S; Taniguchi, N; Uchimura, T; Umekita, Y, 2010) |
| "After adenine dosing, significant hyperphosphatemia, hypocalcemia and secondary hyperparathyroidism (2HPT) were observed during the experimental period of 15 weeks." | 3.75 | Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. ( Fujimori, A; Fukushima, S; Itoh, H; Mizukami, K; Nara, H; Okada, M; Sanagi, M; Takakura, K; Terai, K, 2009) |
| "Tenofovir-related tubule damage characterized by Fanconi syndrome, renal insufficiency and nephrogenic diabetes insipidus has been reported in the adult HIV-infected population." | 3.73 | Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. ( Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A, 2006) |
| "The adenine-containing diet caused renal failure, characterized by crystal deposits, cystic dilatation of tubules, and micro-abscesses." | 3.01 | Functional and histological effects of Anthurium schlechtendalii Kunth extracts on adenine-induced kidney damage of adult Wistar rats. ( Ajibola, OO; Barradas-Dermitz, DM; Calderón-Garcidueñas, AL; Carvajal-Zarrabal, O; López-Amador, N; Nolasco-Hipolito, C, 2023) |
| "Increased risk of lactic acidosis has also been described for those with impaired liver and renal function taking entecavir." | 2.50 | Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. ( Fung, J; Lai, CL; Seto, WK; Yuen, MF, 2014) |
| " Dosing antiretroviral agents with kidney metabolism should be adjusted when eGFR is bellow 50 mL/min/1." | 2.48 | [Kidney and HIV infection]. ( Lescure, FX; Plaisier, E; Ronco, P, 2012) |
| " Despite its proven efficacy and safety, cases of kidney tubular dysfunction have increasingly been reported and concern exists about the risk of nephrotoxicity associated with the long-term use of TFV." | 2.46 | Renal toxicity associated with tenofovir use. ( Alvarez, E; Labarga, P; Rodriguez-Nóvoa, S; Soriano, V, 2010) |
| " Its favorable profile in terms of high efficacy, low toxicity and once-daily dosing makes TDF one of the most attractive antiretroviral agents, and therefore, it is widely used." | 2.45 | Pharmacogenetics of tenofovir treatment. ( Labarga, P; Rodriguez-Novoa, S; Soriano, V, 2009) |
| " Most data on safety and efficacy in this scenario initially came from clinical trials in which tenofovir was combined with non-nucleoside reverse transcriptase inhibitors." | 2.44 | [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors]. ( Fiorante, S; Pulido, F, 2008) |
| " This drug is administered orally in the form of disoproxil ester, which is deesterified to achieve a bioavailability of more than 20%." | 2.44 | [Tenofovir: pharmacology and interactions]. ( Azanza, JR; García Quetglas, E; Gómez-Giu, A; Sádaba, B, 2008) |
| "Acute renal failure is common in HIV-infected patients and is associated with acute infection and medication-related nephrotoxicity." | 2.44 | HIV-1 infection and the kidney: an evolving challenge in HIV medicine. ( de Silva, TI; Dockrell, DH; Griffin, MD; Post, FA, 2007) |
| " These data have now provided a clear and clinically relevant understanding of the individual profiles of drugs within the nucleoside analogue reverse transcriptase inhibitor , HIV protease inhibitor and non-nucleoside analogue reverse transcriptase inhibitor drug classes, and have provided a rational basis for assessing and monitoring these adverse effects in clinical practice." | 2.43 | Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. ( Mallal, S; Nolan, D; Reiss, P, 2005) |
| "Renal fibrosis is an inevitable outcome of various manifestations of progressive chronic kidney diseases (CKD)." | 1.72 | The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice. ( Alolga, RN; Bian, XY; Chen, C; Jiang, H; Li, J; Liu, HL; Liu, SJ; Liu, YF; Shan, JJ; Si, ZL; Tan, NH; Wang, H; Wu, WH; Zhang, ZH; Zhou, W, 2022) |
| "Renal interstitial fibrosis is characterized by the development of myofibroblasts, originating from resident renal and immigrating cells." | 1.62 | Endothelin receptors in renal interstitial cells do not contribute to the development of fibrosis during experimental kidney disease. ( Broeker, KAE; Fuchs, MAA; Neder, TH; Schrankl, J; Wagner, C, 2021) |
| "In individuals with a history of PRT on TDF, 96 weeks of TAF was not associated with recurrent PRT or adverse effects on renal tubular function, bone turnover, or BMD." | 1.62 | Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate. ( Barbini, B; Burling, K; Campbell, L; Cromarty, B; Hamzah, L; Johnson, M; Jones, R; Post, FA; Samarawickrama, A; Williams, D; Winston, A, 2021) |
| "Hyperuricemia is an independent risk factor for chronic kidney disease (CKD)." | 1.56 | Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy. ( Feng, Y; Fu, P; Guo, F; Huang, R; Liao, D; Ma, L; Shi, M; Zeng, X, 2020) |
| "Renal fibrosis is an inevitable course of all kinds of progressive chronic kidney disease (CKD)." | 1.56 | 4-Octyl itaconate protects against renal fibrosis via inhibiting TGF-β/Smad pathway, autophagy and reducing generation of reactive oxygen species. ( He, J; Tan, N; Tian, F; Wang, Z; Zhang, Z, 2020) |
| " In this report, we use metabolomics and proteomics with HK-2 cells and animal models to dissect the molecular pathways underlying nephropathy caused by TFV and its more toxic analog, adefovir (ADV)." | 1.46 | Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity. ( Chen, J; Chen, L; Cheng, L; Chi, W; Deng, H; Huo, Y; Lan, Z; Liu, X; Siegenthaler, JA; Song, W; Sun, K; Xu, L; Zhao, X, 2017) |
| "Renal fibrosis is a common pathological feature of the progression of chronic kidney disease." | 1.46 | Valproic acid attenuates renal fibrosis through the induction of autophagy. ( Doi, S; Doi, T; Kawaoka, K; Masaki, T; Nakashima, A; Ueno, T; Yamada, K, 2017) |
| "Our results demonstrate that apigenin regulates OAT1, and can cause TDI or herb-drug interaction (HDI) when used in combination with acyclovir or adefovir." | 1.46 | Apigenin, a novel candidate involving herb-drug interaction (HDI), interacts with organic anion transporter 1 (OAT1). ( Cao, Y; Chen, J; Fu, W; Li, H; Pang, J; Wu, T; Zhou, P, 2017) |
| "The long-term use of nucleotide analogs increased the risk of nephrotoxicity in patients with CHB." | 1.42 | Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand. ( Kittitrakul, C; Leowattana, W; Nontprasert, A; Phumratanaprapin, W; Poovorawan, K; Sriboonvorakul, N; Tangkijvanich, P; Thu, AM; Wilairatana, P, 2015) |
| "Hepatitis B virus recurrence within 12 months was 4." | 1.42 | Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation. ( Choi, GH; Choi, JS; Joo, DJ; Ju, MK; Kim, MS; Kim, SI; Lee, J; Lee, JG; Lee, JJ; Song, SH, 2015) |
| " The granule form carries a risk of dosing errors and has a particularly strong, unpleasant taste." | 1.40 | Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys. ( , 2014) |
| "Hypertension was diagnosed in 19%, dyslipidemia in 27%, and diabetes mellitus in 3%." | 1.40 | High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors. ( Aiestarán, A; Bonet, J; Bonjoch, A; Clotet, B; Echeverría, P; Juega, J; Negredo, E; Pérez, V; Pérez-Alvarez, N; Puig, J; Romero, R, 2014) |
| "Adenine treatment in rats has been proposed as an animal model of anemia of CKD with high hepcidin levels that mirrors the condition in human patients." | 1.39 | A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. ( Babitt, JL; Brown, DE; Cappellini, MD; Chen, S; Hong, CC; Lin, HY; Stepanek, A; Sun, CC; Theurl, I; Vaja, V; Weiss, G, 2013) |
| " Modification of the dosing interval or discontinuation of ADV was required in seven and three patients, respectively, and none of them showed a further decline in the eGFR." | 1.38 | Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. ( Cho, HC; Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012) |
| "With lamivudine as initial treatment, 62% of patients developed drug resistance after 4 years." | 1.36 | Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. ( Chan, TM; Choy, BY; Tang, CS; Yap, DY; Yuen, MF; Yung, S, 2010) |
| "All three patients progressed to ESRD, within 1 month following renal biopsy in two and after 9 months in one." | 1.36 | Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure. ( Boelkins, M; Broviac, J; Cornell, LD; Fidler, ME; Milliner, DS; Nasr, SH; Sethi, S, 2010) |
| "It became evident that tenofovir DF (TDF) causes a modest and gradual decline in GFR, however, the impact of long-term use of TDF on tubular function has not been fully evaluated." | 1.35 | Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. ( Hanabusa, H; Kinai, E, 2009) |
| " We report 12-month changes in renal profiles among 19 such patients (6 patients with history of and 13 patients with current renal disease) in the HIV Outpatient Study (HOPS) who initiated TDF-containing highly active antiretroviral therapy (HAART) during 2001-2005 with TDF dosed mostly at 300 mg once daily." | 1.35 | Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study. ( Brooks, JT; Buchacz, K; Moorman, A; Wood, KC; Young, B, 2009) |
| "Secondary hyperparathyroidism is characterized by increased parathyroid hormone (PTH) mRNA stability that leads to increased PTH mRNA and serum PTH levels." | 1.35 | Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD. ( Ben-Dov, IZ; Naveh-Many, T; Nechama, M; Silver, J, 2009) |
| "The SCOLTA Project is a prospective, observational, multicenter study involving 25 infectious disease departments in Italy created to assess the incidence of severe adverse events in patients receiving new antiretroviral drugs." | 1.35 | Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. ( Bonfanti, P; Carradori, S; De Socio, GV; Grosso, C; Landonio, S; Madeddu, G; Marconi, P; Melzi, S; Miccolis, S; Mura, MS; Penco, G; Quirino, T; Ricci, E; Rosella, E, 2008) |
| "The EAP enrolled 10 343 patients; serious adverse events (SAEs) were reported in 631 (6%)." | 1.34 | The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. ( Bischofberger, N; Chen, SS; Clotet, B; Cooper, DA; Curtis, S; Gazzard, B; Katlama, C; Lange, J; Lazzarin, A; Montaner, JS; Nelson, MR; Rooney, JF; Schewe, K; Smith, S; Wyatt, C, 2007) |
| "Despite the recent publication of case reports describing various manifestations of tenofovir-related nephrotoxicity, data regarding the incidence of and risk factors for this adverse effect are currently lacking." | 1.33 | Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. ( Antoniou, T; Chirhin, S; Gough, K; Govan, V; Loutfy, M; Raboud, J; Rachlis, A; Yoong, D, 2005) |
| "Renal involvement in patients with systemic lupus erythematosus (SLE) varies from none to full-blown disease." | 1.31 | The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. ( Chung, JH; Kim, HL; Kim, S; Kim, YS; Lee, DS; Lee, JS; Lim, CS; Yang, SH, 2002) |
| "We present a case in which acute renal failure developed after therapy with tenofovir DF in a patient with HIV and stable chronic kidney disease." | 1.31 | Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. ( Coca, S; Perazella, MA, 2002) |
| "When adenine was intravenously administered, UN slightly increased at 1 h, but creatinine was unchanged." | 1.29 | Nephrotoxicity induced by adenine and its analogs: relationship between structure and renal injury. ( Kadota, E; Kawaki, H; Minami, T; Nabeshima, M; Nakagawa, H; Namikawa, K; Okazaki, Y, 1994) |
| "Gout is principally a disease of middle-aged men." | 1.26 | Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family. ( Cameron, JS; Dillon, MJ; Farebrother, DA; Pincott, JR; Simmons, HA; Warren, DJ, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (4.00) | 18.7374 |
| 1990's | 8 (4.00) | 18.2507 |
| 2000's | 62 (31.00) | 29.6817 |
| 2010's | 101 (50.50) | 24.3611 |
| 2020's | 21 (10.50) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, L | 2 |
| Barbini, B | 2 |
| Burling, K | 2 |
| Cromarty, B | 1 |
| Hamzah, L | 4 |
| Johnson, M | 3 |
| Jones, R | 3 |
| Samarawickrama, A | 1 |
| Williams, D | 2 |
| Winston, A | 1 |
| Post, FA | 5 |
| Khan, MA | 1 |
| Nag, P | 1 |
| Grivei, A | 1 |
| Giuliani, KTK | 1 |
| Wang, X | 1 |
| Diwan, V | 1 |
| Hoy, W | 1 |
| Healy, H | 1 |
| Gobe, G | 1 |
| Kassianos, AJ | 1 |
| Zhou, Y | 2 |
| Wei, M | 2 |
| Zhang, M | 1 |
| Zhang, J | 2 |
| Tang, F | 1 |
| Wu, X | 2 |
| Liu, Z | 1 |
| Wang, W | 1 |
| Li, X | 2 |
| Tang, S | 1 |
| Meng, D | 1 |
| Xia, W | 1 |
| Wang, H | 3 |
| Wu, Y | 1 |
| Zhou, X | 1 |
| Du, P | 1 |
| Wang, T | 1 |
| Yang, M | 1 |
| Yin, H | 1 |
| Nakayama, T | 1 |
| Azegami, T | 1 |
| Hayashi, K | 1 |
| Hishikawa, A | 1 |
| Yoshimoto, N | 1 |
| Nakamichi, R | 1 |
| Sugita, E | 1 |
| Itoh, H | 2 |
| Li, A | 1 |
| Ambruso, SL | 1 |
| Oto, OA | 1 |
| Barry, M | 1 |
| Edelstein, CL | 1 |
| Haritha, CV | 1 |
| Lingaraju, MC | 1 |
| Mathesh, K | 1 |
| Jadhav, SE | 1 |
| Shyamkumar, TS | 1 |
| Aneesha, VA | 1 |
| Parida, S | 1 |
| Singh, TU | 1 |
| Kumar, D | 1 |
| Zhou, W | 1 |
| Wu, WH | 1 |
| Si, ZL | 1 |
| Liu, HL | 1 |
| Jiang, H | 1 |
| Liu, YF | 1 |
| Alolga, RN | 1 |
| Chen, C | 1 |
| Liu, SJ | 1 |
| Bian, XY | 1 |
| Shan, JJ | 1 |
| Li, J | 1 |
| Tan, NH | 1 |
| Zhang, ZH | 1 |
| Peng, X | 1 |
| Qiao, B | 1 |
| Peng, M | 1 |
| Deng, N | 1 |
| Yu, R | 1 |
| Tan, Z | 1 |
| Kim, J | 1 |
| Ha, S | 1 |
| Son, M | 1 |
| Kim, D | 2 |
| Kim, MJ | 1 |
| Kim, B | 1 |
| Chung, HY | 1 |
| Chung, KW | 1 |
| Calderón-Garcidueñas, AL | 1 |
| Barradas-Dermitz, DM | 1 |
| Nolasco-Hipolito, C | 1 |
| López-Amador, N | 1 |
| Ajibola, OO | 1 |
| Carvajal-Zarrabal, O | 1 |
| Bailey, AC | 1 |
| Ibrahim, F | 1 |
| Musso, CG | 1 |
| Tian, F | 1 |
| Wang, Z | 1 |
| He, J | 1 |
| Zhang, Z | 1 |
| Tan, N | 1 |
| Klinkhammer, BM | 1 |
| Djudjaj, S | 1 |
| Kunter, U | 1 |
| Palsson, R | 1 |
| Edvardsson, VO | 1 |
| Wiech, T | 1 |
| Thorsteinsdottir, M | 1 |
| Hardarson, S | 1 |
| Foresto-Neto, O | 1 |
| Mulay, SR | 1 |
| Moeller, MJ | 1 |
| Jahnen-Dechent, W | 1 |
| Floege, J | 1 |
| Anders, HJ | 1 |
| Boor, P | 1 |
| Awad, AM | 1 |
| Saleh, MA | 1 |
| Abu-Elsaad, NM | 1 |
| Ibrahim, TM | 1 |
| Surial, B | 1 |
| Béguelin, C | 1 |
| Chave, JP | 1 |
| Stöckle, M | 1 |
| Boillat-Blanco, N | 1 |
| Doco-Lecompte, T | 1 |
| Bernasconi, E | 1 |
| Fehr, J | 1 |
| Günthard, HF | 1 |
| Schmid, P | 1 |
| Walti, LN | 1 |
| Furrer, H | 2 |
| Rauch, A | 1 |
| Wandeler, G | 1 |
| Shi, M | 1 |
| Guo, F | 1 |
| Liao, D | 1 |
| Huang, R | 1 |
| Feng, Y | 1 |
| Zeng, X | 1 |
| Ma, L | 1 |
| Fu, P | 1 |
| Mei, H | 1 |
| Wu, N | 1 |
| Huang, X | 1 |
| Cui, Z | 1 |
| Xu, J | 1 |
| Yang, X | 2 |
| Zeng, F | 1 |
| Wang, K | 1 |
| Jung, SW | 1 |
| Kim, DJ | 1 |
| Kim, YG | 1 |
| Moon, JY | 1 |
| Jeong, KH | 1 |
| Lee, SH | 1 |
| Neder, TH | 1 |
| Schrankl, J | 1 |
| Fuchs, MAA | 1 |
| Broeker, KAE | 1 |
| Wagner, C | 1 |
| Zhao, X | 1 |
| Sun, K | 1 |
| Lan, Z | 1 |
| Song, W | 1 |
| Cheng, L | 1 |
| Chi, W | 1 |
| Chen, J | 2 |
| Huo, Y | 1 |
| Xu, L | 1 |
| Liu, X | 1 |
| Deng, H | 1 |
| Siegenthaler, JA | 1 |
| Chen, L | 1 |
| Gallagher, A | 1 |
| Quan, D | 1 |
| Gracey, DM | 1 |
| Novick, TK | 1 |
| Choi, MJ | 1 |
| Rosenberg, AZ | 1 |
| McMahon, BA | 1 |
| Fine, D | 1 |
| Atta, MG | 2 |
| Law, YXT | 1 |
| Lee, LS | 1 |
| Wu, T | 1 |
| Li, H | 1 |
| Cao, Y | 2 |
| Fu, W | 1 |
| Zhou, P | 1 |
| Pang, J | 1 |
| Chan, L | 1 |
| Asriel, B | 1 |
| Eaton, EF | 1 |
| Wyatt, CM | 2 |
| Rivera-Valdés, JJ | 1 |
| García-Bañuelos, J | 1 |
| Salazar-Montes, A | 1 |
| García-Benavides, L | 1 |
| Dominguez-Rosales, A | 1 |
| Armendáriz-Borunda, J | 1 |
| Sandoval-Rodríguez, A | 1 |
| Negredo, E | 4 |
| Clotet, B | 4 |
| Min, IS | 1 |
| Lee, CH | 1 |
| Shin, IS | 1 |
| Lee, NE | 1 |
| Son, HS | 1 |
| Kim, SB | 1 |
| Seo, SY | 1 |
| Kim, SH | 1 |
| Kim, SW | 1 |
| Lee, SO | 1 |
| Lee, ST | 1 |
| Kim, IH | 1 |
| Fong, TL | 1 |
| Lee, BT | 1 |
| Tien, A | 1 |
| Chang, M | 1 |
| Lim, C | 1 |
| Ahn, A | 1 |
| Bae, HS | 1 |
| Dos Santos, IF | 1 |
| Sheriff, S | 1 |
| Amlal, S | 1 |
| Ahmed, RPH | 1 |
| Thakar, CV | 1 |
| Amlal, H | 1 |
| Garigali, G | 1 |
| Marra, G | 1 |
| Rizzo, V | 1 |
| de Liso, F | 1 |
| Berrettini, A | 1 |
| Daudon, M | 3 |
| Fogazzi, GB | 1 |
| Yang, Y | 1 |
| Wang, P | 1 |
| Ma, Y | 1 |
| Ito, S | 2 |
| Ohno, Y | 1 |
| Tanaka, T | 1 |
| Kobuchi, S | 1 |
| Ayajiki, K | 1 |
| Manabe, E | 1 |
| Masuyama, T | 1 |
| Jun-Ichi, S | 1 |
| Tsujino, T | 1 |
| Qian, YY | 1 |
| Dai, ZJ | 1 |
| Ruan, LY | 1 |
| Pan, YJ | 1 |
| Jin, J | 1 |
| Shi, MT | 1 |
| Zhu, YX | 1 |
| Wu, CM | 1 |
| Hartono, JL | 1 |
| Aung, MO | 1 |
| Dan, YY | 1 |
| Gowans, M | 1 |
| Lim, K | 1 |
| Lee, YM | 1 |
| Lee, GH | 1 |
| Low, HC | 1 |
| Tan, PS | 1 |
| Thwin, MA | 1 |
| Soon, C | 1 |
| Chiu, LL | 1 |
| Khoo, MJ | 1 |
| Koay, E | 1 |
| Lim, SG | 1 |
| Nishijima, T | 2 |
| Shimbo, T | 1 |
| Komatsu, H | 2 |
| Takano, M | 2 |
| Tanuma, J | 1 |
| Tsukada, K | 1 |
| Teruya, K | 1 |
| Gatanaga, H | 2 |
| Kikuchi, Y | 1 |
| Oka, S | 2 |
| Tanaka, M | 1 |
| Suzuki, F | 1 |
| Seko, Y | 1 |
| Hara, T | 1 |
| Kawamura, Y | 1 |
| Sezaki, H | 1 |
| Hosaka, T | 1 |
| Akuta, N | 1 |
| Kobayashi, M | 2 |
| Suzuki, Y | 1 |
| Saitoh, S | 1 |
| Arase, Y | 1 |
| Ikeda, K | 1 |
| Kumada, H | 1 |
| Ichchou, L | 1 |
| Rist, S | 1 |
| Lespessailles, E | 1 |
| Prié, D | 1 |
| Benhamou, CL | 1 |
| Woratanarat, K | 1 |
| Kanjanabuch, T | 1 |
| Suankratay, C | 1 |
| Funk, EK | 1 |
| Shaffer, A | 1 |
| Shivakumar, B | 1 |
| Sneller, M | 1 |
| Polis, MA | 1 |
| Masur, H | 1 |
| Heytens, L | 1 |
| Nelson, A | 1 |
| Kwan, R | 1 |
| Kottilil, S | 1 |
| Kohli, A | 1 |
| Han, Y | 1 |
| Xie, J | 1 |
| Cui, Q | 1 |
| Zhang, L | 1 |
| Li, Y | 3 |
| Song, X | 1 |
| Zhu, T | 1 |
| Li, T | 1 |
| Foisy, MM | 1 |
| Hughes, C | 1 |
| Hills-Nieminen, C | 1 |
| Singh, AE | 1 |
| Joffe, AM | 1 |
| Pradat, P | 1 |
| Le Pogam, MA | 1 |
| Okon, JB | 1 |
| Trolliet, P | 1 |
| Miailhes, P | 1 |
| Brochier, C | 1 |
| Maynard, M | 1 |
| Bailly, F | 1 |
| Zoulim, F | 1 |
| Cotte, L | 1 |
| Pammi, M | 1 |
| Arumainayagam, J | 1 |
| Kumari, B | 1 |
| Ahmed-Jushuf, I | 1 |
| Carlin, EM | 1 |
| Chandramani, S | 1 |
| Riddell, L | 1 |
| Ghanem, M | 1 |
| Das, S | 1 |
| Tanaka, H | 1 |
| Arai, M | 1 |
| Tomoda, Y | 1 |
| Wada, T | 1 |
| Yago, K | 1 |
| Satoh, M | 1 |
| Giacomet, V | 2 |
| Cattaneo, D | 2 |
| Viganò, A | 2 |
| Nannini, P | 1 |
| Manfredini, V | 1 |
| Ramponi, G | 1 |
| Clementi, E | 1 |
| Zuccotti, GV | 2 |
| Myer, L | 1 |
| Kamkuemah, M | 1 |
| Kaplan, R | 1 |
| Bekker, LG | 1 |
| van Griensven, J | 2 |
| Phirum, L | 1 |
| Thai, S | 1 |
| Buyze, J | 1 |
| Lynen, L | 2 |
| Koenig, KF | 1 |
| Kalbermatter, S | 1 |
| Menter, T | 1 |
| Graber, P | 1 |
| Kiss, D | 1 |
| Jabłonowska, E | 1 |
| Wójcik, K | 1 |
| Piekarska, A | 1 |
| Ryom, L | 1 |
| Mocroft, A | 1 |
| Lundgren, JD | 1 |
| Fung, J | 1 |
| Seto, WK | 1 |
| Lai, CL | 2 |
| Yuen, MF | 2 |
| Gervasoni, C | 1 |
| Milazzo, L | 1 |
| Pezzani, D | 1 |
| Fucile, S | 1 |
| Mwafongo, A | 1 |
| Nkanaunena, K | 1 |
| Zheng, Y | 1 |
| Hogg, E | 1 |
| Samaneka, W | 1 |
| Mulenga, L | 1 |
| Siika, A | 1 |
| Currier, J | 1 |
| Lockman, S | 1 |
| Hughes, MD | 1 |
| Hosseinipour, M | 1 |
| Ezinga, M | 1 |
| Wetzels, JF | 1 |
| Bosch, ME | 1 |
| van der Ven, AJ | 1 |
| Burger, DM | 1 |
| Jose, S | 1 |
| Campbell, LJ | 2 |
| Hill, T | 1 |
| Fisher, M | 2 |
| Leen, C | 1 |
| Gilson, R | 1 |
| Walsh, J | 1 |
| Nelson, M | 1 |
| Hay, P | 1 |
| Chadwick, D | 1 |
| Nitsch, D | 2 |
| Sabin, CA | 1 |
| Gupta, SK | 2 |
| Anderson, AM | 1 |
| Ebrahimi, R | 1 |
| Fralich, T | 1 |
| Graham, H | 1 |
| Scharen-Guivel, V | 1 |
| Flaherty, JF | 1 |
| Fortin, C | 1 |
| Kalayjian, RC | 1 |
| Rachlis, A | 2 |
| Milman, Z | 1 |
| Axelrod, JH | 1 |
| Heyman, SN | 1 |
| Nachmansson, N | 1 |
| Abramovitch, R | 1 |
| Pujari, SN | 1 |
| Smith, C | 1 |
| Makane, A | 1 |
| Youle, M | 1 |
| Bele, V | 1 |
| Joshi, K | 1 |
| Dabhade, D | 1 |
| Bhagani, S | 1 |
| Zeng, Y | 1 |
| Li, S | 1 |
| Wu, J | 2 |
| Chen, W | 1 |
| Sun, H | 1 |
| Peng, W | 1 |
| Yu, X | 1 |
| Jafari, A | 1 |
| Khalili, H | 1 |
| Dashti-Khavidaki, S | 1 |
| Boettiger, DC | 1 |
| Saphonn, V | 1 |
| Lee, MP | 1 |
| Phanuphak, P | 1 |
| Pham, TT | 1 |
| Heng Sim, BL | 1 |
| Kumarasamy, N | 1 |
| Van Nguyen, K | 1 |
| Kantipong, P | 1 |
| Kamarulzaman, A | 1 |
| Chaiwarith, R | 1 |
| Kiertiburanakul, S | 1 |
| Law, MG | 1 |
| Bonjoch, A | 2 |
| Juega, J | 1 |
| Puig, J | 2 |
| Pérez-Alvarez, N | 2 |
| Aiestarán, A | 1 |
| Echeverría, P | 2 |
| Pérez, V | 1 |
| Romero, R | 1 |
| Bonet, J | 1 |
| Gorriz, JL | 1 |
| Gutiérrez, F | 3 |
| Trullàs, JC | 1 |
| Arazo, P | 1 |
| Arribas, JR | 1 |
| Barril, G | 1 |
| Cervero, M | 1 |
| Cofán, F | 1 |
| Domingo, P | 1 |
| Estrada, V | 1 |
| Fulladosa, X | 1 |
| Galindo, MJ | 1 |
| Gràcia, S | 1 |
| Iribarren, JA | 1 |
| Knobel, H | 1 |
| López-Aldeguer, J | 1 |
| Lozano, F | 1 |
| Martínez-Castelao, A | 1 |
| Martínez, E | 1 |
| Mazuecos, MA | 1 |
| Miralles, C | 1 |
| Montañés, R | 1 |
| Palacios, R | 1 |
| Pérez-Elías, MJ | 1 |
| Portilla, J | 1 |
| Praga, M | 1 |
| Quereda, C | 1 |
| Rivero, A | 1 |
| Santamaría, JM | 1 |
| Sanz, J | 2 |
| Miró, JM | 1 |
| Maggi, P | 2 |
| Montinaro, V | 2 |
| Leone, A | 1 |
| Fasano, M | 1 |
| Volpe, A | 2 |
| Bellacosa, C | 2 |
| Grattagliano, V | 1 |
| Coladonato, L | 1 |
| Lapadula, G | 1 |
| Santantonio, T | 1 |
| Angarano, G | 2 |
| Crean, D | 1 |
| Bellwon, P | 1 |
| Aschauer, L | 1 |
| Limonciel, A | 1 |
| Moenks, K | 1 |
| Hewitt, P | 1 |
| Schmidt, T | 1 |
| Herrgen, K | 1 |
| Dekant, W | 1 |
| Lukas, A | 1 |
| Bois, F | 1 |
| Wilmes, A | 1 |
| Jennings, P | 1 |
| Leonard, MO | 1 |
| Mandala, J | 1 |
| Nanda, K | 1 |
| Wang, M | 1 |
| De Baetselier, I | 1 |
| Deese, J | 1 |
| Lombaard, J | 1 |
| Owino, F | 1 |
| Malahleha, M | 1 |
| Manongi, R | 1 |
| Taylor, D | 1 |
| Van Damme, L | 1 |
| Mitra, S | 1 |
| Priscilla, R | 1 |
| Rajeev, K | 1 |
| Sauradeep, S | 1 |
| Rajkumar, S | 1 |
| Cherian, AO | 1 |
| Shimizu, M | 1 |
| Furusyo, N | 1 |
| Ikezaki, H | 1 |
| Ogawa, E | 1 |
| Hayashi, T | 1 |
| Ihara, T | 1 |
| Harada, Y | 1 |
| Toyoda, K | 1 |
| Murata, M | 1 |
| Hayashi, J | 1 |
| Lee, JG | 1 |
| Lee, J | 1 |
| Lee, JJ | 1 |
| Song, SH | 1 |
| Ju, MK | 1 |
| Choi, GH | 1 |
| Kim, MS | 1 |
| Choi, JS | 1 |
| Kim, SI | 1 |
| Joo, DJ | 1 |
| Thu, AM | 1 |
| Poovorawan, K | 1 |
| Kittitrakul, C | 1 |
| Nontprasert, A | 1 |
| Sriboonvorakul, N | 1 |
| Phumratanaprapin, W | 1 |
| Tangkijvanich, P | 1 |
| Leowattana, W | 1 |
| Wilairatana, P | 1 |
| Kamijo-Ikemori, A | 1 |
| Sugaya, T | 1 |
| Hibi, C | 1 |
| Nakamura, T | 1 |
| Murase, T | 1 |
| Oikawa, T | 1 |
| Hoshino, S | 1 |
| Hisamichi, M | 1 |
| Hirata, K | 1 |
| Kimura, K | 1 |
| Shibagaki, Y | 1 |
| Kawaoka, K | 1 |
| Doi, S | 1 |
| Nakashima, A | 1 |
| Yamada, K | 1 |
| Ueno, T | 1 |
| Doi, T | 1 |
| Masaki, T | 1 |
| Luo, Q | 1 |
| Deng, Y | 1 |
| Cheng, F | 1 |
| Kang, J | 1 |
| Zhong, S | 1 |
| Zhang, D | 1 |
| Zeng, W | 1 |
| Hayashi, S | 1 |
| Oe, Y | 1 |
| Fushima, T | 1 |
| Sato, E | 1 |
| Sato, H | 1 |
| Takahashi, N | 1 |
| Libório, AB | 1 |
| Andrade, L | 1 |
| Pereira, LV | 1 |
| Sanches, TR | 1 |
| Shimizu, MH | 1 |
| Seguro, AC | 1 |
| Crane, HM | 1 |
| Kestenbaum, B | 1 |
| Harrington, RD | 1 |
| Kitahata, MM | 1 |
| Winston, J | 2 |
| Deray, G | 3 |
| Hawkins, T | 1 |
| Szczech, L | 1 |
| Wyatt, C | 2 |
| Young, B | 2 |
| Nechama, M | 1 |
| Ben-Dov, IZ | 3 |
| Silver, J | 2 |
| Naveh-Many, T | 2 |
| Azanza, JR | 1 |
| García Quetglas, E | 1 |
| Sádaba, B | 1 |
| Gómez-Giu, A | 1 |
| Pulido, F | 1 |
| Fiorante, S | 1 |
| Barril Cuadrado, G | 1 |
| de Los Santos Gil, I | 1 |
| Mallolas, J | 1 |
| Terai, K | 1 |
| Nara, H | 1 |
| Takakura, K | 1 |
| Mizukami, K | 1 |
| Sanagi, M | 1 |
| Fukushima, S | 1 |
| Fujimori, A | 1 |
| Okada, M | 1 |
| Kinai, E | 1 |
| Hanabusa, H | 1 |
| Romero, E | 1 |
| Hernández, JM | 1 |
| Jarilla, F | 1 |
| Woodward, CL | 1 |
| Hall, AM | 3 |
| Williams, IG | 1 |
| Madge, S | 1 |
| Copas, A | 1 |
| Nair, D | 1 |
| Edwards, SG | 1 |
| Johnson, MA | 1 |
| Connolly, JO | 2 |
| Buchacz, K | 1 |
| Moorman, A | 1 |
| Wood, KC | 1 |
| Brooks, JT | 1 |
| Gallant, JE | 4 |
| Moore, RD | 2 |
| Rodriguez-Novoa, S | 4 |
| Labarga, P | 4 |
| Soriano, V | 4 |
| Galitzer, H | 1 |
| Nasr, SH | 1 |
| Sethi, S | 1 |
| Cornell, LD | 1 |
| Milliner, DS | 1 |
| Boelkins, M | 1 |
| Broviac, J | 1 |
| Fidler, ME | 1 |
| Agarwala, R | 1 |
| Mohan, S | 1 |
| Herlitz, LC | 1 |
| Cheng, JT | 1 |
| Wever, K | 1 |
| van Agtmael, MA | 1 |
| Carr, A | 1 |
| Flandre, P | 1 |
| Oyama, Y | 1 |
| Hashiguchi, T | 1 |
| Taniguchi, N | 1 |
| Tancharoen, S | 1 |
| Uchimura, T | 1 |
| Biswas, KK | 1 |
| Kawahara, K | 1 |
| Nitanda, T | 1 |
| Umekita, Y | 1 |
| Lotz, M | 1 |
| Maruyama, I | 1 |
| D'avolio, A | 1 |
| Barreiro, P | 1 |
| Albalate, M | 1 |
| Vispo, E | 1 |
| Solera, C | 1 |
| Siccardi, M | 1 |
| Bonora, S | 2 |
| Di Perri, G | 2 |
| Alvarez, E | 1 |
| Crum-Cianflone, N | 1 |
| Ganesan, A | 1 |
| Teneza-Mora, N | 1 |
| Riddle, M | 1 |
| Medina, S | 1 |
| Barahona, I | 1 |
| Brodine, S | 1 |
| Yap, DY | 1 |
| Tang, CS | 1 |
| Yung, S | 1 |
| Choy, BY | 1 |
| Chan, TM | 1 |
| Shuvy, M | 1 |
| Cooper, RD | 2 |
| Wiebe, N | 1 |
| Smith, N | 1 |
| Keiser, P | 1 |
| Naicker, S | 1 |
| Tonelli, M | 2 |
| Langer, S | 1 |
| Kokozidou, M | 1 |
| Heiss, C | 1 |
| Kranz, J | 1 |
| Kessler, T | 1 |
| Paulus, N | 1 |
| Krüger, T | 1 |
| Jacobs, MJ | 1 |
| Lente, C | 1 |
| Koeppel, TA | 1 |
| Soler-Palacín, P | 1 |
| Melendo, S | 1 |
| Noguera-Julian, A | 1 |
| Fortuny, C | 1 |
| Navarro, ML | 1 |
| Mellado, MJ | 1 |
| Garcia, L | 1 |
| Uriona, S | 1 |
| Martín-Nalda, A | 1 |
| Figueras, C | 1 |
| Hendry, BM | 1 |
| Calza, L | 2 |
| Trapani, F | 2 |
| Tedeschi, S | 1 |
| Piergentili, B | 1 |
| Manfredi, R | 2 |
| Colangeli, V | 2 |
| Viale, P | 2 |
| Gracey, D | 1 |
| Post, J | 1 |
| MacLeod, C | 1 |
| McKenzie, P | 1 |
| Harbord, N | 1 |
| Yao, F | 1 |
| Zhang, R | 1 |
| Fu, R | 1 |
| He, W | 1 |
| Pushpakom, SP | 1 |
| Liptrott, NJ | 1 |
| Albalater, M | 1 |
| Hopper-Borge, E | 1 |
| Back, DJ | 1 |
| Khoo, S | 1 |
| Pirmohamed, M | 1 |
| Owen, A | 1 |
| Sopheak, T | 1 |
| Koole, O | 1 |
| Verpooten, GA | 1 |
| Kim, YJ | 1 |
| Cho, HC | 1 |
| Sinn, DH | 1 |
| Gwak, GY | 1 |
| Choi, MS | 1 |
| Koh, KC | 1 |
| Paik, SW | 1 |
| Yoo, BC | 1 |
| Lee, JH | 1 |
| Li, SW | 1 |
| Hu, LJ | 1 |
| Wu, QH | 1 |
| Huang, P | 1 |
| Cao, HY | 1 |
| Vrouenraets, SM | 1 |
| Wit, FW | 1 |
| Fernandez Garcia, E | 1 |
| Moyle, GJ | 1 |
| Jackson, AG | 1 |
| Allavena, C | 1 |
| Raffi, F | 1 |
| Jayaweera, DT | 1 |
| Mauss, S | 2 |
| Katlama, C | 2 |
| Slama, L | 1 |
| Hardy, WD | 1 |
| Dejesus, E | 1 |
| van Eeden, A | 1 |
| Reiss, P | 2 |
| Yoshino, M | 1 |
| Yagura, H | 1 |
| Kushida, H | 1 |
| Yonemoto, H | 1 |
| Bando, H | 1 |
| Ogawa, Y | 1 |
| Yajima, K | 1 |
| Kasai, D | 1 |
| Taniguchi, T | 1 |
| Watanabe, D | 1 |
| Nishida, Y | 2 |
| Kuwahara, T | 1 |
| Uehira, T | 1 |
| Shirasaka, T | 1 |
| Stöhr, W | 1 |
| Reid, A | 1 |
| Walker, AS | 1 |
| Ssali, F | 1 |
| Munderi, P | 1 |
| Mambule, I | 1 |
| Kityo, C | 1 |
| Grosskurth, H | 1 |
| Gilks, CF | 1 |
| Gibb, DM | 1 |
| Hakim, J | 1 |
| Schleenvoigt, BT | 1 |
| Stallmach, A | 1 |
| Pletz, MW | 1 |
| Pietanza, S | 1 |
| Graziano, G | 1 |
| Strippoli, GF | 1 |
| Gupta, A | 1 |
| Bugeja, A | 1 |
| Kirpalani, D | 1 |
| Plaisier, E | 1 |
| Lescure, FX | 1 |
| Ronco, P | 1 |
| Pontrelli, G | 1 |
| Cotugno, N | 1 |
| Amodio, D | 1 |
| Zangari, P | 1 |
| Tchidjou, HK | 1 |
| Baldassari, S | 1 |
| Palma, P | 1 |
| Bernardi, S | 1 |
| Islam, FM | 1 |
| Jansson, J | 1 |
| Wilson, DP | 1 |
| Gish, RG | 1 |
| Clark, MD | 1 |
| Kane, SD | 1 |
| Shaw, RE | 1 |
| Mangahas, MF | 1 |
| Baqai, S | 1 |
| Bollée, G | 1 |
| Harambat, J | 1 |
| Bensman, A | 1 |
| Knebelmann, B | 1 |
| Ceballos-Picot, I | 1 |
| Rossotti, R | 1 |
| Moioli, MC | 1 |
| Chianura, L | 1 |
| Errante, I | 1 |
| Orcese, C | 1 |
| Orso, M | 1 |
| Schiantarelli, C | 1 |
| Schlacht, I | 1 |
| Travi, G | 1 |
| Vigo, B | 1 |
| Villa, MR | 1 |
| Volonterio, A | 1 |
| Puoti, M | 1 |
| Estany, C | 1 |
| Higasa, K | 1 |
| Tsuchiya, K | 1 |
| Hayashida, T | 1 |
| Salvadori, C | 1 |
| Magistrelli, E | 1 |
| Di Bari, MA | 1 |
| Borderi, M | 1 |
| Laprise, C | 1 |
| Baril, JG | 1 |
| Dufresne, S | 1 |
| Trottier, H | 1 |
| Coffin, CS | 1 |
| Fung, SK | 1 |
| Ma, MM | 1 |
| Sun, CC | 1 |
| Vaja, V | 1 |
| Chen, S | 1 |
| Theurl, I | 1 |
| Stepanek, A | 1 |
| Brown, DE | 1 |
| Cappellini, MD | 1 |
| Weiss, G | 1 |
| Hong, CC | 1 |
| Lin, HY | 1 |
| Babitt, JL | 1 |
| Skowron, G | 1 |
| Kuritzkes, DR | 1 |
| Thompson, MA | 1 |
| Squires, KE | 1 |
| Goodwin, SD | 1 |
| Dusak, BA | 1 |
| Tolson, JM | 1 |
| Stevens, M | 1 |
| Yuen, GJ | 1 |
| Rooney, JF | 2 |
| Kim, HL | 1 |
| Lee, DS | 1 |
| Yang, SH | 1 |
| Lim, CS | 1 |
| Chung, JH | 1 |
| Kim, S | 1 |
| Lee, JS | 1 |
| Kim, YS | 1 |
| Coca, S | 1 |
| Perazella, MA | 3 |
| Antoniou, T | 2 |
| Narita, I | 1 |
| Goto, S | 1 |
| Saito, N | 1 |
| Song, J | 1 |
| Omori, K | 1 |
| Kondo, D | 1 |
| Sakatsume, M | 1 |
| Gejyo, F | 1 |
| KINOSHITA, Y | 2 |
| JAHRMAERKER, H | 1 |
| Izzedine, H | 2 |
| Isnard-Bagnis, C | 1 |
| Hulot, JS | 2 |
| Vittecoq, D | 2 |
| Cheng, A | 2 |
| Jais, CK | 1 |
| Launay-Vacher, V | 2 |
| Masiá, M | 2 |
| Padilla, S | 2 |
| Ramos, JM | 1 |
| Pascual, J | 1 |
| Saumoy, M | 1 |
| Vidal, F | 1 |
| Peraire, J | 1 |
| Sauleda, S | 1 |
| Vea, AM | 1 |
| Viladés, C | 1 |
| Ribera, E | 1 |
| Richart, C | 1 |
| Rifkin, BS | 1 |
| Koguchi, T | 1 |
| Koguchi, H | 1 |
| Nakajima, H | 1 |
| Takano, S | 1 |
| Yamamoto, Y | 1 |
| Innami, S | 1 |
| Maekawa, A | 1 |
| Tadokoro, T | 1 |
| Berger, F | 1 |
| Schmutz, G | 1 |
| Staszewski, S | 1 |
| Parish, MA | 1 |
| Keruly, JC | 1 |
| Nolan, D | 1 |
| Mallal, S | 1 |
| Raboud, J | 1 |
| Chirhin, S | 1 |
| Yoong, D | 1 |
| Govan, V | 1 |
| Gough, K | 1 |
| Loutfy, M | 1 |
| Jülg, BD | 1 |
| Bogner, JR | 1 |
| Crispin, A | 1 |
| Goebel, FD | 1 |
| Cánovas, V | 1 |
| Orozco, C | 1 |
| Hussain, S | 1 |
| Khayat, A | 1 |
| Tolaymat, A | 1 |
| Rathore, MH | 1 |
| Cirino, CM | 1 |
| Kan, VL | 1 |
| Shepp, DH | 1 |
| Panda, A | 1 |
| Yang, AM | 1 |
| Li, YQ | 1 |
| Li, HS | 1 |
| Song, CS | 1 |
| Ren, Y | 1 |
| Yin, JX | 1 |
| Madeddu, G | 2 |
| Quirino, T | 2 |
| Carradori, S | 2 |
| Ricci, E | 2 |
| Grosso, C | 2 |
| Penco, G | 2 |
| De Socio, G | 1 |
| Rossella, E | 1 |
| Palvarini, L | 1 |
| Marconi, P | 2 |
| Melzi, S | 2 |
| Mura, MS | 2 |
| Bonfanti, P | 2 |
| Tan, J | 1 |
| Lok, AS | 1 |
| Sax, PE | 1 |
| Klotman, PE | 1 |
| Schiff, E | 1 |
| Hadziyannis, S | 1 |
| Neuhaus, P | 1 |
| Terrault, N | 1 |
| Colombo, M | 1 |
| Tillmann, H | 1 |
| Samuel, D | 1 |
| Zeuzem, S | 1 |
| Villeneuve, JP | 1 |
| Arterburn, S | 1 |
| Borroto-Esoda, K | 1 |
| Brosgart, C | 1 |
| Chuck, S | 1 |
| Gitman, MD | 1 |
| Hirschwerk, D | 1 |
| Baskin, CH | 1 |
| Singhal, PC | 1 |
| Gérard, L | 1 |
| Chazallon, C | 1 |
| Taburet, AM | 1 |
| Girard, PM | 1 |
| Aboulker, JP | 1 |
| Piketty, C | 1 |
| Nelson, MR | 1 |
| Montaner, JS | 1 |
| Cooper, DA | 1 |
| Gazzard, B | 1 |
| Lazzarin, A | 1 |
| Schewe, K | 1 |
| Lange, J | 1 |
| Curtis, S | 1 |
| Chen, SS | 1 |
| Smith, S | 1 |
| Bischofberger, N | 1 |
| De Socio, GV | 1 |
| Rosella, E | 1 |
| Miccolis, S | 1 |
| Landonio, S | 1 |
| Fux, CA | 1 |
| Christen, A | 1 |
| Zgraggen, S | 1 |
| Mohaupt, MG | 1 |
| Martelli, L | 1 |
| Cafarelli, L | 1 |
| Borgonovo, S | 1 |
| Beretta, S | 1 |
| Rombolà, G | 1 |
| Mora, S | 1 |
| Hou, P | 1 |
| Chen, Y | 1 |
| Ding, J | 1 |
| Li, G | 1 |
| Zhang, H | 1 |
| de Silva, TI | 1 |
| Griffin, MD | 1 |
| Dockrell, DH | 1 |
| Essig, M | 1 |
| Duval, X | 1 |
| Kaied, FA | 1 |
| Iordache, L | 1 |
| Gervais, A | 1 |
| Longuet, P | 1 |
| Blanchet, F | 1 |
| Peytavin, G | 1 |
| Leport, C | 1 |
| Szczech, LA | 1 |
| Goicoechea, M | 1 |
| Liu, S | 1 |
| Best, B | 1 |
| Sun, S | 1 |
| Jain, S | 1 |
| Kemper, C | 1 |
| Witt, M | 1 |
| Diamond, C | 1 |
| Haubrich, R | 1 |
| Louie, S | 1 |
| Hu, BC | 1 |
| Chu, SL | 1 |
| Wang, GL | 1 |
| Gao, PJ | 1 |
| Zhu, DL | 1 |
| Wang, JG | 1 |
| Fine, DM | 1 |
| Lucas, GM | 1 |
| He, LQ | 1 |
| Bounous, G | 1 |
| Sutherland, NG | 1 |
| Mcardle, AH | 1 |
| Gurd, FN | 1 |
| Farebrother, DA | 1 |
| Pincott, JR | 1 |
| Simmons, HA | 1 |
| Warren, DJ | 1 |
| Dillon, MJ | 1 |
| Cameron, JS | 1 |
| Konishi, N | 1 |
| Takeshita, K | 1 |
| Yasui, H | 1 |
| Minami, T | 1 |
| Nakagawa, H | 1 |
| Nabeshima, M | 1 |
| Kadota, E | 1 |
| Namikawa, K | 1 |
| Kawaki, H | 1 |
| Okazaki, Y | 1 |
| Tsuda, H | 1 |
| Matsumoto, K | 1 |
| Iwase, T | 1 |
| Baba, H | 1 |
| Yokozawa, T | 2 |
| Fujioka, K | 1 |
| Oura, H | 2 |
| Nonaka, G | 1 |
| Nishioka, I | 1 |
| Estepa-Maurice, L | 1 |
| Hennequin, C | 1 |
| Marfisi, C | 1 |
| Bader, C | 1 |
| Lacour, B | 1 |
| Highleyman, L | 1 |
| Gröbner, W | 1 |
| Walter-Sack, I | 1 |
| Story, DL | 1 |
| Shrader, RE | 1 |
| Theriault, LL | 1 |
| Lumijarvi, DL | 1 |
| Shenoy, TS | 1 |
| Savaiano, DA | 1 |
| Shaffer, RH | 1 |
| Ho, CY | 1 |
| Clifford, AJ | 1 |
| Fujitsuka, N | 1 |
| Delbarre, F | 1 |
| Cartier, P | 1 |
| Auscher, C | 1 |
| de Géry, A | 1 |
| Hamet, M | 1 |
| Forbes, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Cohort Study to Assess the Safety and Efficacy of Replacing Tenofovir Disoproxil Fumarate by Tenofovir Alafenamide in HIV/HBV-coinfected Patients With Mild or Moderate Renal Dysfunction[NCT03115736] | Phase 2 | 24 participants (Actual) | Interventional | 2017-05-23 | Completed | ||
| "Analysis of Proximal Renal Tubular Function of Real World Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF"[NCT02957994] | Phase 4 | 82 participants (Actual) | Interventional | 2016-12-22 | Active, not recruiting | ||
| The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate[NCT05313477] | Phase 4 | 64 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | ||
| Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients[NCT00872417] | Phase 4 | 750 participants (Anticipated) | Interventional | 2009-03-31 | Not yet recruiting | ||
| Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection[NCT02556333] | Phase 2 | 1 participants (Actual) | Interventional | 2015-09-16 | Terminated | ||
| Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Effectiveness and Safety Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women[NCT00625404] | Phase 3 | 2,120 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Severe Impairment of Solute-Free Water Clearance in Patients With HIV Infection[NCT01869010] | 30 participants (Actual) | Observational | 2010-01-31 | Completed | |||
| Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir[NCT02588287] | 14 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.[NCT03126370] | Phase 4 | 10 participants (Actual) | Interventional | 2018-01-08 | Completed | ||
| Impact of Vitamin D Enteral Supplementation on Hepcidin Serum Levels and Transfusion Requirements in Surgical and Critically Ill Patients[NCT03001687] | 40 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | |||
| Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients[NCT00551655] | 684 participants (Actual) | Observational | 2007-05-31 | Completed | |||
| Safety and Efficacy of Tenofovir Alafenamide for Chronic Hepatitis B Patients With Decompensated Liver Disease[NCT04683341] | Phase 4 | 100 participants (Anticipated) | Interventional | 2020-09-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An HIV RNA decline of >=0.5 log by day 10 will be considered to be an adequate virologic response, to proceed to the second phase of the study. (NCT02556333)
Timeframe: 10 days
| Intervention | log HIV RNA copies/mL (Number) |
|---|---|
| TAF Treatment | 0.01 |
CD4+ T-cell Count at the Time of HIV Seroconversion through 16 weeks (NCT00625404)
Timeframe: Up to 16 weeks
| Intervention | cells/mL (Mean) |
|---|---|
| Truvada Arm | 579.3 |
| Placebo Arm | 601.4 |
Repeat specimens were collected to confirm chemistry toxicities. Grade 2 or higher serum creatinine toxicity was defined as ≥1.4 times the upper limit of normal (NCT00625404)
Timeframe: cumulative toxicity through 52 weeks of product use and 4 weeks post product
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 4 |
| Placebo Arm | 2 |
Grade 3 or higher ALT elevation was defined as ≥ 2.6 times the upper limit of normal (NCT00625404)
Timeframe: Through 52 weeks on product and 4 weeks post-product
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 6 |
| Placebo Arm | 8 |
Grade 3 or higher AST elevation was defined as ≥ 2.6 times the upper limit of normal (NCT00625404)
Timeframe: Through 52 weeks on product and 4 weeks post-product
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 3 |
| Placebo Arm | 1 |
Repeat specimens were collected to confirm chemistry toxicities. Grade 3 phosphorus reduction was defined as ≤2.4mg/dL (NCT00625404)
Timeframe: Through 52 weeks on product and 4 weeks post-product
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 45 |
| Placebo Arm | 40 |
The total number of adverse events in the placebo and Truvada arms during and within 4 weeks after study product administration. (NCT00625404)
Timeframe: 10-26 months per site
| Intervention | Number of adverse events (Number) |
|---|---|
| Truvada Arm | 2257 |
| Placebo Arm | 2384 |
"Genotypic resistance to FTC and/or tenofovir at the time of HIV diagnosis and 4 weeks later. If resistance was present, testing was repeated at weeks 12, 24, 36 and 52 as necessary (resistance testing will stop if no resistance is detected).~participants were classified as having resistance if they had one or more visits in which resistance was detected, even if the resistance became undetectable over time." (NCT00625404)
Timeframe: up to 52 weeks
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 3 |
| Placebo Arm | 1 |
HIV Seroconversion, with time to infection refined based on PCR results obtained from stored specimens. (NCT00625404)
Timeframe: Cumulative HIV infection between enrollment and 52 weeks
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 33 |
| Placebo Arm | 35 |
Difference in mean number of reported sexual partners between final study visit and enrollment visit (NCT00625404)
Timeframe: Up to 52 weeks
| Intervention | mean number of sexual partners (Mean) |
|---|---|
| Truvada Arm | -0.14 |
| Placebo Arm | -0.13 |
Pill counts and participant report of adherence to once-daily pill taking reported as mean days study product could have been used according to pill counts (NCT00625404)
Timeframe: Up to 52 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| Truvada Arm | 87 |
| Placebo Arm | 89 |
Viral load at the time of HIV detection, HIV conversion and through 16 weeks (NCT00625404)
Timeframe: up to 16 weeks
| Intervention | log copies/mL (Log Mean) |
|---|---|
| Truvada Arm | 4.40 |
| Placebo Arm | 4.37 |
Reported complications during pregnancy, including spontaneous abortion, vaginal or uterine bleeding, emergency c-section and other complications (NCT00625404)
Timeframe: up to 60 weeks
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 20 |
| Placebo Arm | 10 |
Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 weeks and 28 weeks
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 3466 |
| TAF With a Boosted PI | 743 |
| TAF With a Boosted PI and LDV/SOF | 868 |
Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 and 28 weeks
| Intervention | fmol/2x7mm punches (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 36014 |
| TAF With a Boosted PI | 6735 |
| TAF With a Boosted PI and LDV/SOF | 6100 |
Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1). (NCT03126370)
Timeframe: 12 weeks, and 24 weeks and 28 weeks
| Intervention | fmol/10^6 cells (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 83.0 |
| TAF With a Boosted PI | 926 |
| TAF With a Boosted PI and LDV/SOF | 1129 |
Change in estimated glomerular filtration rate (eGFR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
| Intervention | mL/min/1.73 m^2 (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 86.7 |
| TAF With a Boosted PI | 91.0 |
| TAF With a Boosted PI and LDV/SOF | 88.1 |
Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
| Intervention | mg/g (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 134 |
| TAF With a Boosted PI | 118 |
| TAF With a Boosted PI and LDV/SOF | 97.3 |
Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
| Intervention | ug/g (Geometric Mean) | |
|---|---|---|
| β2M:Cr ratio | RBP:Cr ratio | |
| TAF With a Boosted PI | 224 | 242 |
| TAF With a Boosted PI and LDV/SOF | 178 | 146 |
| TDF With a Boosted PI | 419 | 436 |
26 reviews available for adenine and Kidney Diseases
| Article | Year |
|---|---|
Functional and histological effects of Anthurium schlechtendalii Kunth extracts on adenine-induced kidney damage of adult Wistar rats.
Topics: Adenine; Adult; Animals; Araceae; Humans; Inflammation; Kidney; Kidney Diseases; Plant Extracts; Rat | 2023 |
Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Drug Interactions; Glomerular Filtration Rate; Hep | 2018 |
Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons.
Topics: Adenine; Anti-Retroviral Agents; HIV Infections; Humans; Immunosuppression Therapy; Kidney Diseases; | 2014 |
Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.
Topics: Acidosis, Lactic; Adenine; Administration, Oral; Antiviral Agents; Arabinofuranosyluracil; Dose-Resp | 2014 |
Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.
Topics: Adenine; Animals; Anti-HIV Agents; HIV Infections; Humans; Incidence; Kidney Diseases; Organophospho | 2014 |
Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis.
Topics: Adenine; Creatinine; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Kidney Diseas | 2016 |
Kidney disease in patients with HIV infection and AIDS.
Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Risk Factors; Tenofovir | 2008 |
[Tenofovir: pharmacology and interactions].
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Biological Availability; Biotransformation; Child | 2008 |
[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cohort St | 2008 |
[Management of renal toxicity in HIV-positive patients. What to measure, how to measure it and how frequently].
Topics: Adenine; Algorithms; Anti-HIV Agents; beta 2-Microglobulin; Clinical Trials as Topic; Cohort Studies | 2008 |
Pharmacogenetics of tenofovir treatment.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; HIV-1; Humans; Kidney Diseases; Ki | 2009 |
Renal toxicity associated with tenofovir use.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Hu | 2010 |
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Tenofovir | 2010 |
Renal disease associated with antiretroviral therapy in the treatment of HIV.
Topics: Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Indinavir; Kidney Disea | 2011 |
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Disea | 2011 |
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Disea | 2011 |
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Disea | 2011 |
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Disea | 2011 |
Novel nephrotoxins.
Topics: Adenine; Alcohols; Angiogenesis Inhibitors; Anticonvulsants; Antipsychotic Agents; Dasatinib; Diphos | 2011 |
[Kidney and HIV infection].
Topics: Adenine; AIDS-Associated Nephropathy; Anti-HIV Agents; Biopsy; Black People; ErbB Receptors; Female; | 2012 |
Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chronic | 2012 |
Adenine phosphoribosyltransferase deficiency.
Topics: Adenine; Adenine Phosphoribosyltransferase; Allopurinol; Animals; Biomarkers; Disease Progression; E | 2012 |
Update on tenofovir toxicity in the kidney.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Hepatitis B; HIV Infections; Humans; Kidney; Ki | 2013 |
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardi | 2005 |
[Renal toxicity in HIV-infected patients receiving HAART including tenofovir].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; HIV Infections; | 2006 |
Renal safety of tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; Humans; Kidney; Kidney Diseases; | 2007 |
HIV-1 infection and the kidney: an evolving challenge in HIV medicine.
Topics: Acute Disease; Acute Kidney Injury; Adenine; AIDS-Associated Nephropathy; Angiotensin-Converting Enz | 2007 |
Kidney biopsy in HIV: beyond HIV-associated nephropathy.
Topics: Acute Disease; Adenine; AIDS-Associated Nephropathy; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2008 |
[A case of adenine phosphoribosyltransferase (APRT) deficiency discovered by urine examination].
Topics: Adenine; Adenine Phosphoribosyltransferase; Adult; Allopurinol; Crystallization; Homozygote; Humans; | 1994 |
14 trials available for adenine and Kidney Diseases
| Article | Year |
|---|---|
Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
Topics: Adenine; Alanine; Creatinine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine | 2020 |
Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; Hum | 2013 |
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Deoxycytidine; Drug Therapy, Combination; Emtricitabin | 2014 |
Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Blac | 2014 |
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
Topics: Adenine; Adult; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Dyslipidemias; Emtr | 2011 |
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Did | 2011 |
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
Topics: Adenine; Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy | 2002 |
Renal safety of tenofovir in HIV treatment-experienced patients.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Kidney Disease | 2004 |
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
Topics: Adenine; Adult; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Male; O | 2005 |
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Creatinine; Female; HIV Infec | 2005 |
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2007 |
Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cre | 2007 |
Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Female; Glomerular Filtration Rate; H | 2007 |
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
Topics: Adenine; Adult; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV P | 2008 |
160 other studies available for adenine and Kidney Diseases
| Article | Year |
|---|---|
Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Creatinine; Cystatin C; Female; HIV Infections; Humans; Ki | 2021 |
Adenine overload induces ferroptosis in human primary proximal tubular epithelial cells.
Topics: Adenine; Aldehydes; Animals; Epithelial Cells; Ferroptosis; Flavanones; Humans; Iron; Kidney Disease | 2022 |
Adefovir accumulation in the renal interstitium triggers mast cell degranulation and promotes renal interstitial fibrosis.
Topics: Adenine; Animals; Cell Degranulation; Disease Models, Animal; Fibrosis; Humans; Kidney Diseases; Kid | 2022 |
Capsaicin ameliorates renal fibrosis by inhibiting TGF-β1-Smad2/3 signaling.
Topics: Adenine; Animals; Cadherins; Capsaicin; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; M | 2022 |
Mucin-fused myeloid-derived growth factor (MYDGF164) exhibits a prolonged serum half-life and alleviates fibrosis in chronic kidney disease.
Topics: Adenine; Animals; Disease Models, Animal; Fibrosis; Half-Life; Humans; Intercellular Signaling Pepti | 2022 |
Vaccination against connective tissue growth factor attenuates the development of renal fibrosis.
Topics: Adenine; Animals; Connective Tissue Growth Factor; Fibrosis; Kidney; Kidney Diseases; Mice; Renal In | 2022 |
A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib.
Topics: Adenine; Aged, 80 and over; Endothelial Cells; ErbB Receptors; Glomerulonephritis, Membranoprolifera | 2022 |
PRE-084 ameliorates adenine-induced renal fibrosis in rats.
Topics: Adenine; Animals; Creatinine; Fibrosis; Keratins; Kidney Diseases; Matrix Metalloproteinase 2; Morph | 2022 |
The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice.
Topics: Adenine; Animals; Bacteroides fragilis; Biological Products; Disease Models, Animal; Fibrosis; Gastr | 2022 |
Gut-Kidney Impairment Process of Adenine Combined with
Topics: Acetic Acid; Adenine; Animals; Bacteroides; Colitis; Creatinine; Diarrhea; Disease Models, Animal; F | 2022 |
TLR7 activation by miR-21 promotes renal fibrosis by activating the pro-inflammatory signaling pathway in tubule epithelial cells.
Topics: Adenine; Animals; Epithelial Cells; Fibrosis; Inflammation; Kidney Diseases; Mice; MicroRNAs; NF-kap | 2023 |
4-Octyl itaconate protects against renal fibrosis via inhibiting TGF-β/Smad pathway, autophagy and reducing generation of reactive oxygen species.
Topics: Adenine; Animals; Antioxidants; Autophagy; Fibrosis; Humans; Kidney Diseases; Male; Protective Agent | 2020 |
Cellular and Molecular Mechanisms of Kidney Injury in 2,8-Dihydroxyadenine Nephropathy.
Topics: Adenine; Adenine Phosphoribosyltransferase; Adult; Animals; Cohort Studies; Diet; Disease Models, An | 2020 |
Erlotinib can halt adenine induced nephrotoxicity in mice through modulating ERK1/2, STAT3, p53 and apoptotic pathways.
Topics: Adenine; Animals; Disease Models, Animal; Fibrosis; Humans; Kidney; Kidney Diseases; MAP Kinase Sign | 2020 |
Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Female; Glomerular Filtration Rate; Hepatitis B; Hepatitis | 2020 |
Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy.
Topics: Adenine; Animals; Biphenyl Compounds; Cytokines; Fatty Acid-Binding Proteins; Fibrosis; Hepatitis A | 2020 |
Possible mechanisms by which silkworm faeces extract ameliorates adenine-induced renal anaemia in rats.
Topics: Adenine; Anemia; Animals; Bombyx; Disease Models, Animal; Erythropoietin; Feces; Hepcidins; Humans; | 2021 |
Renal Aging Resembles a Continuum Between Normal and Diseased Kidneys That Potentiates Inflammatory Response to Injury.
Topics: Adenine; Aging; Animals; Cytokines; Disease Models, Animal; Inflammation; Kidney Diseases; Male; Mic | 2021 |
Endothelin receptors in renal interstitial cells do not contribute to the development of fibrosis during experimental kidney disease.
Topics: Adenine; Animals; Fibrosis; Gene Deletion; Gene Expression Regulation; Kidney; Kidney Diseases; Mice | 2021 |
Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity.
Topics: Adenine; Animals; Anti-HIV Agents; Cell Line; Cell Proliferation; Cell Survival; Glucose; Glycolysis | 2017 |
Improvement in renal function and resolution of proteinuria in an HIV-infected patient switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Alanine; Antiviral Agents; Drug Substitution; Female; HIV Infections; Humans; Kidney Diseas | 2017 |
Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Mitoc | 2017 |
Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma.
Topics: Acute Disease; Adenine; Female; Flank Pain; Hematoma; Humans; Kidney Diseases; Lymphoma, Mantle-Cell | 2018 |
Apigenin, a novel candidate involving herb-drug interaction (HDI), interacts with organic anion transporter 1 (OAT1).
Topics: Acyclovir; Adenine; Animals; Antiviral Agents; Apigenin; Cell Survival; Chromatography, High Pressur | 2017 |
Human adipose derived stem cells regress fibrosis in a chronic renal fibrotic model induced by adenine.
Topics: Adenine; Adipose Tissue; Animals; Cells, Cultured; Fibrosis; Gene Expression Profiling; Humans; Kidn | 2017 |
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, | 2018 |
Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate.
Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Female; Glomerular Filtration Rate; | 2019 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal | 2019 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal | 2019 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal | 2019 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal | 2019 |
Adenine acts in the kidney as a signaling factor and causes salt- and water-losing nephropathy: early mechanism of adenine-induced renal injury.
Topics: Adenine; Animals; Aquaporin 2; Arginine Vasopressin; Cyclic AMP; Diet; Dose-Response Relationship, D | 2019 |
A virtuous diagnostic and therapeutic roadmap triggered by a motivated and skilful urinary sediment examination.
Topics: Adenine; Humans; Kidney Diseases; Urinalysis; Urologic Diseases | 2019 |
Adefovir accumulation and nephrotoxicity in renal interstitium: Role of organic anion transporters of kidney.
Topics: Adenine; Animals; Antiviral Agents; Kidney Diseases; Kidney Tubules; Organic Anion Transporters; Org | 2019 |
Neutrophil/lymphocyte ratio elevation in renal dysfunction is caused by distortion of leukocyte hematopoiesis in bone marrow.
Topics: Adenine; Aged; Aged, 80 and over; Animals; Biomarkers; Bone Marrow; Carbon; Cardiovascular Diseases; | 2019 |
Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible?
Topics: Adenine; Aged; Dose-Response Relationship, Drug; Fanconi Syndrome; Female; Hepatitis B, Chronic; Hum | 2019 |
Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Asian People; Creatinine; Dose-Response Relationship, Drug; Female | 2013 |
Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study.
Topics: Adenine; Adult; Alpha-Globulins; Anti-Retroviral Agents; beta 2-Microglobulin; Biomarkers; Chi-Squar | 2013 |
Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Creatinine; Drug Therapy, Combination; Female; Glomerular Fi | 2014 |
Reversible increase in FGF23 in a hypophosphatemic renal and bone disease linked to antiviral therapy by adefovir.
Topics: Adenine; Aged; Antiviral Agents; Bone Diseases; Female; Fibroblast Growth Factor-23; Fibroblast Grow | 2013 |
Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Huma | 2013 |
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Com | 2013 |
Tenofovir-related nephrotoxicity: an ongoing clinical challenge.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organo | 2013 |
Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chro | 2013 |
Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; CD4 Lymphocyte Count; Cycl | 2013 |
Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Combinations; | 2013 |
Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.
Topics: Adenine; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Ma | 2013 |
Low prevalence of renal dysfunction in HIV-infected pregnant women: implications for guidelines for the prevention of mother-to-child transmission of HIV.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Contraindications; Creatinine; F | 2013 |
A clinical prediction score for targeted creatinine testing before initiating tenofovir-based antiretroviral treatment in Cambodia.
Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Clinical Medicine; Creatinine; Cross-Sectional Studies; D | 2014 |
Recurrent bone fractures due to tenofovir-induced renal phosphate wasting.
Topics: Adenine; Adult; Anti-HIV Agents; Fractures, Stress; HIV Infections; Humans; Kidney Diseases; Male; O | 2014 |
Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Fat | 2014 |
Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients.
Topics: Adenine; Adult; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Kidney Diseases; Male; Oligop | 2014 |
Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Comorbidity; Cross-Sectional | 2014 |
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Female; Glomerular Fi | 2014 |
Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Creatinine; Fanconi Syndrome; Female; Glomeru | 2014 |
Assessment with unenhanced MRI techniques of renal morphology and hemodynamic changes during acute kidney injury and chronic kidney disease in mice.
Topics: Acute Kidney Injury; Adenine; Animals; Contrast Media; Hemodynamics; Kidney; Kidney Diseases; Magnet | 2014 |
Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; India; Kidney Disea | 2014 |
Autophagy inhibitors promoted aristolochic acid I induced renal tubular epithelial cell apoptosis via mitochondrial pathway but alleviated nonapoptotic cell death in mouse acute aritolochic acid nephropathy model.
Topics: Adenine; Animals; Apoptosis; Aristolochia; Aristolochic Acids; Autophagy; Chloroquine; Drugs, Chines | 2014 |
Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; Child; Dose-Response Relationship, Drug; HIV Infections; Hu | 2014 |
A clinical prediction tool for targeted pre-antiretroviral therapy creatinine testing applied to the TREAT Asia HIV observational database cohort.
Topics: Adenine; Anti-HIV Agents; Clinical Medicine; Creatinine; Decision Support Techniques; Female; HIV In | 2014 |
High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors.
Topics: Adenine; Adult; Age Factors; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; D | 2014 |
[Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients].
Topics: Adenine; Algorithms; Anti-HIV Agents; Biopsy; Cardiovascular Diseases; Disease Management; Evidence- | 2014 |
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Bone Diseases; Drug-Related Side Effects and Adverse Reactio | 2015 |
Development of an in vitro renal epithelial disease state model for xenobiotic toxicity testing.
Topics: Adenine; Cell Line; Epithelium; Gene Expression Regulation; Humans; Hypoxia; Kidney Diseases; Kidney | 2015 |
Renal tubular dysfunction associated with tenofovir therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Developing Countries; Diagnosis, Differential; Female; | 2014 |
Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Chi-Square Distribution; Fem | 2015 |
Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation.
Topics: Adenine; Female; Hepatitis B; Humans; Incidence; Kidney Diseases; Lamivudine; Liver Transplantation; | 2015 |
Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Follow-Up Studies; Guanine; Hepatitis B, Chron | 2015 |
Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury.
Topics: Adenine; Animals; Biomarkers; Fatty Acid-Binding Proteins; Febuxostat; Kidney; Kidney Diseases; Male | 2016 |
Valproic acid attenuates renal fibrosis through the induction of autophagy.
Topics: Actins; Adenine; Animals; Autophagy; Cell Line; Collagen Type I; Cytoprotection; Disease Models, Ani | 2017 |
Protease-activated receptor 2 exacerbates adenine-induced renal tubulointerstitial injury in mice.
Topics: Adenine; Animals; Enzyme-Linked Immunosorbent Assay; Factor V; Factor Xa; Fibrin; Fibrosis; Gene Exp | 2017 |
Rosiglitazone reverses tenofovir-induced nephrotoxicity.
Topics: Adenine; Animals; Drug-Related Side Effects and Adverse Reactions; Glomerular Filtration Rate; Hypog | 2008 |
Tenofovir-associated decline in renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease In | 2008 |
Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD.
Topics: 3' Untranslated Regions; Adenine; Aniline Compounds; Animals; Calcium; Chronic Disease; Disease Mode | 2009 |
[Conclusions. Tenofovir].
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; HIV Reverse Transcriptase; Hu | 2008 |
Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.
Topics: Adenine; Animals; Aortic Diseases; Biomarkers; Blood Urea Nitrogen; Calcinosis; Calcium; Calcium Car | 2009 |
Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Therapy, Combination; Glomerular Filtration Rate; HIV In | 2009 |
[Renal tuberculosis and human immunodeficiency virus infection].
Topics: Acute Kidney Injury; Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral | 2009 |
Tenofovir-associated renal and bone toxicity.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Fanconi Syndrome; Female; Glycosuria; HIV Infections; H | 2009 |
Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
Topics: Adenine; Adult; Aged; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Ac | 2009 |
HIV therapy may be given safely in resource-limited settings without routine laboratory monitoring.
Topics: Adenine; Anti-HIV Agents; Diagnostic Tests, Routine; Glomerular Filtration Rate; Health Resources; H | 2009 |
Renal function with use of a tenofovir-containing initial antiretroviral regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtratio | 2009 |
Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease.
Topics: Adenine; Animals; Chronic Disease; Down-Regulation; Fibroblast Growth Factor-23; Fibroblast Growth F | 2010 |
Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure.
Topics: Adenine; Adenine Phosphoribosyltransferase; Adult; Allopurinol; Crystallization; Diagnosis, Differen | 2010 |
The case: 41-year-old HIV patient with proteinuria and progressive renal dysfunction. Tenofovir toxicity.
Topics: Adenine; Adult; Anti-HIV Agents; Biopsy; Disease Progression; Humans; Kidney; Kidney Diseases; Kidne | 2010 |
Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.
Topics: Adenine; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Disease | 2010 |
Tenofovir and changes in renal function.
Topics: Adenine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Re | 2010 |
High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy.
Topics: Adenine; Animals; Blood Urea Nitrogen; Chemokine CCL2; Creatinine; Epithelial Cells; Granuloma; HMGB | 2010 |
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.
Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Organophosp | 2010 |
Prevalence and factors associated with renal dysfunction among HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Fem | 2010 |
Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Female; Guanine; H | 2010 |
Acquired DHA nephropathy in rats.
Topics: Adenine; Animals; Crystallization; Kidney Diseases; Rats | 2010 |
Chronic kidney disease aggravates arteriovenous fistula damage in rats.
Topics: Adenine; Animals; Arteriovenous Shunt, Surgical; Blood Pressure; Calcinosis; Chronic Disease; Constr | 2010 |
Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.
Topics: Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infections; Humans; K | 2011 |
Is tenofovir-related renal toxicity incompletely reversible?
Topics: Adenine; Adult; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases | 2011 |
Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; | 2011 |
Improvement in chronic renal impairment following the discontinuation of tenofovir in two HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Biopsy; Chronic Disease | 2011 |
[Preventive and therapeutic effects of quercetin on hyperuricemia and renal injury in rats].
Topics: Adenine; Animals; Antioxidants; Blood Urea Nitrogen; Creatinine; Ethambutol; Hyperuricemia; Kidney D | 2011 |
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Kidney; Kidney Diseases; Kidney Tubules; M | 2011 |
Determination of kidney function before tenofovir initiation: four-fold difference in need of tenofovir dose reduction depending on method used.
Topics: Adenine; Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rat | 2011 |
Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients.
Topics: Adenine; Adolescent; Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Female; G | 2012 |
[The influence of suoquan capsule on the mRNA expression of CYP11B2 in deficiency of the kidney and diuresis rats].
Topics: Adenine; Aldosterone; Animals; Corticosterone; Cytochrome P-450 CYP11B2; Disease Models, Animal; Diu | 2011 |
Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Drug Administration Schedule; Female; Glomerular | 2012 |
Tenofovir induced acute kidney injury in a patient with unilateral renal agenesis despite initially non-impaired renal function.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Congenital Abnormalities; HIV Infections; Huma | 2011 |
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
Topics: Adenine; Anti-HIV Agents; Biomarkers; Cohort Studies; Cytochromes c; Deoxycytidine; Dideoxynucleosid | 2012 |
Tenofovir-induced nephrotoxicity: myths and facts.
Topics: Adenine; Animals; Anti-HIV Agents; Evidence-Based Medicine; HIV Infections; HIV-1; Humans; Kidney Di | 2012 |
Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Female; HIV Infections; HIV Protease Inhibitors; Humans | 2012 |
Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Creatinine; Female; Glomerular Filtration Ra | 2012 |
Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: a case-control study.
Topics: Adenine; Adult; Aged; Case-Control Studies; CD4 Lymphocyte Count; Chi-Square Distribution; Deoxycyti | 2012 |
High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Kidney; Kidne | 2012 |
Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.
Topics: Adenine; Adult; Cohort Studies; Cross-Sectional Studies; Female; Genetic Predisposition to Disease; | 2012 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabi | 2013 |
Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Cohort Studies; Female; Follow-Up Studies; Glomerular Filtr | 2013 |
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
Topics: Adenine; Allied Health Personnel; Antibodies, Viral; Antiviral Agents; Canada; Coinfection; Drug Res | 2012 |
A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats.
Topics: Adenine; Anemia, Iron-Deficiency; Animals; Anti-Infective Agents; Blotting, Western; Bone Morphogene | 2013 |
FDA recommends hepatitis B drug.
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Approval; Hepatitis B; Humans; Kidney | 2002 |
The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE.
Topics: 5' Flanking Region; Adenine; Adult; Chemokine CCL2; Disease Progression; Female; Gene Expression Reg | 2002 |
Adefovir (Hepsera) for chronic hepatitis B infection.
Topics: Adenine; Administration, Oral; Controlled Clinical Trials as Topic; Creatinine; Drug Resistance, Vir | 2002 |
Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Chronic Disease; HIV Infections; Humans; Kidne | 2002 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; HIV Infections; HIV- | 2003 |
Angiotensinogen gene variation and renoprotective efficacy of renin-angiotensin system blockade in IgA nephropathy.
Topics: Adenine; Adult; Alleles; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2003 |
Inhibition of aminonucleoside renal lesions in rats adenine, adenosine triphosphate (ATP) and flavine adenine dinucleotide (FAD).
Topics: Adenine; Adenine Nucleotides; Adenosine Triphosphate; Animals; Flavin-Adenine Dinucleotide; Kidney; | 1963 |
[ON THE ADENINE NUCLEOTIDE CONTENT OF ERYTHROCYTES IN RENAL INSUFFICIENCY].
Topics: Acidosis; Acute Kidney Injury; Adenine; Adenine Nucleotides; Erythrocytes; Humans; Kidney Diseases; | 1964 |
[Inhibition of aminonucleoside renal lesions in rats by adenine, adenosine triphosphate (ATP) and flavine adenine dinucleotide (FAD)].
Topics: Adenine; Adenine Nucleotides; Adenosine Triphosphate; Animals; Coenzymes; Flavin-Adenine Dinucleotid | 1962 |
Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Didanosine; Drug Interactions; Drug Therapy, Combinatio | 2004 |
Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Mitochondrial; HIV Infections; HIV-1; Humans; Kidney Diseases; | 2004 |
Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Fanconi Syndrome; Humans; Kidne | 2004 |
Dietary fiber suppresses elevation of uric acid and urea nitrogen concentrations in serum of rats with renal dysfunction induced by dietary adenine.
Topics: Adenine; Animals; Blood Urea Nitrogen; Cellulose; Chitin; Chitosan; Creatinine; Diet; Dietary Fiber; | 2004 |
Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
Topics: Adenine; Anti-HIV Agents; Creatinine; Cross-Sectional Studies; Cystatin C; Cystatins; Glomerular Fil | 2005 |
Tenofovir and renal toxicity.
Topics: Adenine; Anti-HIV Agents; Creatinine; Humans; Kidney Diseases; Organophosphonates; Tenofovir; Viral | 2004 |
Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Female; HIV Infections; Humans; Hypophosphatemia; Kidne | 2005 |
Tenofovir and changes in renal function.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Kidney Dise | 2005 |
Progression of renal impairment under therapy with tenofovir.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Disease Progression; Glomerular Filtration Rate; HIV | 2005 |
Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Case-Control Studies; Creatinine; Dose-Response Rela | 2005 |
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
Topics: Adenine; Anti-HIV Agents; Child; Diabetes Insipidus, Nephrogenic; Didanosine; Drug Therapy, Combinat | 2006 |
Hypokalemia in HIV patients on tenofovir.
Topics: Adenine; Adolescent; Adult; Body Weight; Child; Didanosine; Drug Therapy, Combination; Female; HIV I | 2006 |
Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.
Topics: Adenine; Creatinine; Dose-Response Relationship, Drug; Fanconi Syndrome; Glomerular Filtration Rate; | 2006 |
HIV-associated nephropathy and drug-induced renal injury.
Topics: Adenine; AIDS-Associated Nephropathy; Anti-HIV Agents; Humans; Kidney Diseases; Male; Middle Aged; O | 2006 |
[Affection of Bushen Shengjing pill on NO and NOS in testicle and ante-oxidization of rat with spermatogenic cell injury].
Topics: Adenine; Animals; Drug Combinations; Drugs, Chinese Herbal; Fertility Agents, Male; Kidney Diseases; | 2006 |
Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; H | 2007 |
Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans | 2007 |
Tenofovir-induced kidney injury.
Topics: Adenine; Animals; Anti-HIV Agents; Humans; Kidney Diseases; Organophosphonates; Tenofovir | 2007 |
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
Topics: Adenine; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anti-Retroviral Agents; Antivi | 2007 |
Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Cohort Studies; Comorbidity; Female; Follow-Up Studies | 2008 |
Effect of tenofovir on renal glomerular and tubular function.
Topics: Adenine; Anti-Retroviral Agents; Case-Control Studies; Cross-Sectional Studies; Glomerular Filtratio | 2007 |
A novel mutation of COL4A3 presents a different contribution to Alport syndrome and thin basement membrane nephropathy.
Topics: Adenine; Adult; Aged; Asian People; Aspartic Acid; Autoantigens; Base Sequence; Collagen Type IV; Co | 2007 |
Is phosphatemia the best tool to monitor renal tenofovir toxicity?
Topics: Adenine; Biomarkers; Creatinine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases | 2007 |
Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context.
Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Organophosphonates; Reverse Transc | 2008 |
Association between genetic variation in transforming growth factors beta1 and beta3 and renal dysfunction in non-diabetic Chinese.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Albuminuria; Asian People; Creatinine; Cytosine; Female; Ge | 2008 |
[Change of aquaporin-1 in rat models of kidney-yang-deficiency syndrome].
Topics: Adenine; Animals; Aquaporin 1; Diagnosis, Differential; Disease Models, Animal; Hydrocortisone; Kidn | 2008 |
The prophylactic use of an "elemental" diet in experimental hemorrhagic shock and intestinal ischemia.
Topics: Adenine; Adenosine Triphosphate; Animals; Blood Pressure; Chromatography; Digestion; Dogs; Epitheliu | 1967 |
Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family.
Topics: Adenine; Adult; Animals; Child; Child, Preschool; Female; Gout; Humans; Kidney; Kidney Diseases; Swi | 1981 |
Nephrotoxicity induced by adenine and its analogs: relationship between structure and renal injury.
Topics: Adenine; Animals; Blood Urea Nitrogen; Creatinine; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred | 1994 |
Enhanced neoplastic lesion development with adenine-induced experimental multicystic nephropathy by adenine--a model system for the analysis of renal tumor generation in long-term hemodialysis patients.
Topics: Adenine; Adenoma; Animals; Diethylnitrosamine; Epithelium; Hyperplasia; Kidney Diseases; Kidney Neop | 1994 |
Effects of rhubarb tannins on renal function in rats with renal failure.
Topics: Adenine; Animals; Biflavonoids; Catechin; Glomerular Filtration Rate; Kidney; Kidney Diseases; Male; | 1993 |
Fourier transform infrared microscopy identification of crystal deposits in tissues: clinical importance in various pathologies.
Topics: Adenine; Adult; Aged; Apatites; Biopsy; Calcium Phosphates; Child, Preschool; Crystallization; Femal | 1996 |
New drugs in development.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials a | 1998 |
FDA panel fails to recommend adefovir approval. Food and Drug Administration.
Topics: Adenine; Anti-HIV Agents; Drug Approval; HIV Infections; Humans; Kidney Diseases; Salvage Therapy; U | 1999 |
[Hyperuricemia and gout--diagnosis].
Topics: Adenine; Adult; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Female; Go | 2002 |
Effects of dietary protein, adenine, and allopurinol on growth and metabolism of rats.
Topics: Adenine; Allopurinol; Animals; Body Weight; Caseins; Dietary Proteins; Kidney; Kidney Diseases; Kidn | 1977 |
Production of methylguanidine from creatinine in normal rats and rats with renal failure.
Topics: Adenine; Animals; Creatinine; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Kidney; | 1990 |
[Enzymopathic gout. Dyspurinia due to hypoxanthine-guanine-phosphoribosyl-transferase deficiency. Occurrence and clinical characteristics of enzyme repression].
Topics: Adenine; Adult; Age Factors; Allopurinol; Enzyme Repression; Female; Gout; Guanine; Humans; Hypoxant | 1970 |
Attempts to alter kidney calcification in the magnesium-deficient rat.
Topics: Adenine; Adenosine Triphosphate; Animals; Body Weight; Brain; Calcinosis; Diet; Dinitrophenols; Ethi | 1971 |